Rapt Therapeutics (NASDAQ:RAPT) Earns Sell (D-) Rating from Weiss Ratings

Key Points

• Rapt Therapeutics received a "sell (D-)" rating from Weiss Ratings, signaling a cautious outlook on the stock.
• In contrast, other analysts, including Leerink Partners and HC Wainwright, have issued more favorable ratings with a consensus recommendation of "Moderate Buy" and a price target of $23.50.
• Despite recent fluctuations in ratings, the stock opened at $29.44 and has a market capitalization of $486.94 million, reflecting its ongoing volatility in the market.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Other equities research analysts have also recently issued reports about the stock. Leerink Partnrs raised shares of Rapt Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, September 25th. JPMorgan Chase & Co. raised shares of Rapt Therapeutics from an "underweight" rating to a "neutral" rating and set a $14.00 target price on the stock in a research report on Wednesday, July 30th. HC Wainwright raised their target price on shares of Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a research report on Thursday, July 10th. Lifesci Capital raised shares of Rapt Therapeutics to a "strong-buy" rating and set a $31.00 target price on the stock in a research report on Tuesday, July 22nd. Finally, Wall Street Zen raised shares of Rapt Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $23.50.

Rapt Therapeutics Price Performance

Rapt Therapeutics stock opened at $29.44 on Wednesday. Rapt Therapeutics has a 12-month low of $5.67 and a 12-month high of $32.35. The stock has a market capitalization of $486.94 million, a P/E ratio of -2.08 and a beta of 0.23. The firm's 50-day moving average is $16.15 and its two-hundred day moving average is $11.10.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.04). As a group, analysts forecast that Rapt Therapeutics will post -2.14 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of RAPT. ADAR1 Capital Management LLC raised its holdings in Rapt Therapeutics by 408.4% in the first quarter. ADAR1 Capital Management LLC now owns 5,970,768 shares of the company's stock valued at $7,284,000 after buying an additional 4,796,455 shares during the period. Nantahala Capital Management LLC raised its stake in shares of Rapt Therapeutics by 303.1% during the first quarter. Nantahala Capital Management LLC now owns 5,012,927 shares of the company's stock valued at $6,116,000 after purchasing an additional 3,769,414 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Rapt Therapeutics during the first quarter valued at approximately $188,000. Nuveen LLC purchased a new stake in shares of Rapt Therapeutics during the first quarter valued at approximately $143,000. Finally, Checkpoint Capital L.P. purchased a new stake in shares of Rapt Therapeutics during the first quarter valued at approximately $134,000. Hedge funds and other institutional investors own 99.09% of the company's stock.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.